News
FDA Approves Sacituzumab Govitecan-hziy for First-Line Treatment of Metastatic Triple Negative Breas
The U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).
This approval builds on years of research and a growing understanding of metastatic breast cancer. For people living with mTNBC, today's approval means an additional first-line treatment option
Datroway approved in the US
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
